Pfizer Inc. (PFE)

Pfizer Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 29, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	7,523	7,787	8,051	2,173	31,401	22,459
Depreciation & Amortization	6,587	6,592	7,013	6,290	5,064	5,191
Stock-Based Compensation	901	799	877	525	872	1,182
Other Adjustments	2,143	1,881	-132	1,886	-2,431	-8,713
Change in Receivables	-	-263	-109	347	261	-3,811
Changes in Inventories	-	561	-854	-1,169	-591	-1,125
Changes in Accounts Payable	-	-469	-1,023	-300	1,191	1,242
Changes in Accrued Expenses	-	-3,667	-3,115	595	-1,449	18,721
Changes in Income Taxes Payable	-	-2,805	-1,345	-982	-545	-1,166
Changes in Other Operating Activities	-6,757	1,289	3,380	-663	-4,506	-1,057
Operating Cash Flow	11,984	11,704	12,744	8,700	29,267	32,580
Operating Cash Flow Growth	-14.33%	-8.16%	46.48%	-70.27%	-10.17%	126.20%
Capital Expenditures	-2,501	-2,629	-2,909	-3,907	-3,236	-2,711
Purchases of Investments	-14,366	-14,650	-10,313	-31,178	-38,297	-39,525
Proceeds from Sale of Investments	19,681	19,054	5,698	41,243	45,462	28,096
Payments for Business Acquisitions	-	-6,927	-	-43,430	-22,997	-
Proceeds from Business Divestments	-	6,311	7,040	-	-	-
Other Investing Activities	272	-2,510	3,138	4,995	3,285	-8,393
Investing Cash Flow	-3,840	-1,351	2,652	-32,278	-15,783	-22,546
Short-Term Debt Issued	-537	-796	6,317	7,686	3,669	-96
Short-Term Debt Repaid	-151	-2,199	-11,226	-3	-3,887	-
Net Short-Term Debt Issued (Repaid)	-688	-2,995	-4,909	7,683	-218	-96
Long-Term Debt Issued	2,953	2,921	-2,250	28,262	-3,298	-1,007
Net Long-Term Debt Issued (Repaid)	2,953	2,921	-2,250	28,262	-3,298	-1,007
Repurchase of Common Stock	-	-	-	-	-2,000	-
Net Common Stock Issued (Repurchased)	-	-	-	-	-2,000	-
Common Dividends Paid	-9,779	-9,771	-9,512	-9,247	-8,983	-8,729
Other Financing Activities	-386	-458	-469	-631	-335	16
Financing Cash Flow	-7,933	-10,304	-17,140	26,066	-14,834	-9,816
Effect of Exchange Rate Changes on Cash and Cash Equivalents	67	41	-66	-40	-165	-59
Net Cash Flow	279	91	-1,810	2,448	-1,515	159
Free Cash Flow	9,483	9,075	9,835	4,793	26,031	29,869
Free Cash Flow Growth	4.50%	-7.73%	105.19%	-81.59%	-12.85%	145.29%
FCF Margin	14.98%	14.50%	15.46%	8.05%	25.73%	36.74%
Free Cash Flow Per Share	1.66	1.59	1.73	0.84	4.54	5.23
Levered Free Cash Flow	7,084	6,569	2,019	37,928	23,784	39,971
Unlevered Free Cash Flow	4,850	6,658	9,198	2,035	27,327	41,554

Updated May 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q